Our top pick for
Beginners

Celularity Inc is a shell companies business based in the US. Celularity shares (GXGX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $10.13 |
---|---|
52-week range | $7.73 - $12.58 |
50-day moving average | $10.06 |
200-day moving average | $10.14 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.13 from 2021-05-28
1 week (2022-06-19) | N/A |
---|---|
1 month (2022-05-26) | N/A |
3 months (2022-03-26) | N/A |
6 months (2021-12-26) | N/A |
1 year (2021-06-30) | -0.49% |
---|---|
2 years (2020-06-30) | -0.69% |
3 years (2019-06-26) | N/A |
5 years (2017-06-26) | N/A |
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -1.29% |
Return on equity TTM | -52.61% |
Profit margin | 0% |
Book value | $0.67 |
Market capitalisation | $201.6 million |
TTM: trailing 12 months
We're not expecting Celularity to pay a dividend over the next 12 months.
Celularity Inc. , a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.